Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Semjonow

Showing results (21-30 of 102) with videos related to

Pageof 11
Sort By:
Urology|June 18, 2003
Bicycle riding has no important impact on total and free prostate-specific antigen serum levels in older menHans-Joachim Luboldt, Klaus D Peck, Frank Oberpenning, et al.
Urologic Oncology|December 17, 2013
Tumor percentage but not number of tumor foci predicts disease-free survival after radical prostatectomy especially in high-risk patientsReemt Hinkelammert, Okyaz Eminaga, Olaf Bettendorf, et al.
International Journal of Molecular Sciences|September 13, 2016
Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate CancerKatrin Schlack, Laura-Maria Krabbe, Manfred Fobker, et al.
Urologic Oncology|February 26, 2013
The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/mlOkyaz Eminaga, Reemt Hinkelammert, Ulf Titze, et al.
Acta Oncologica (Stockholm, Sweden)|May 25, 2011
Tumor markers in prostate cancer I: blood-based markersShahrokh F Shariat, Axel Semjonow, Hans Lilja, et al.
The Prostate|March 28, 2013
High-grade prostatic intraepithelial neoplasia (HGPIN) and topographical distribution in 1,374 prostatectomy specimens: existence of HGPIN near prostate cancerOkyaz Eminaga, Reemt Hinkelammert, Mahmoud Abbas, et al.
Reviews in Urology|October 16, 2007
Twenty Years of PSA: From Prostate Antigen to Tumor MarkerGabriela De Angelis, Harry G Rittenhouse, Stephen D Mikolajczyk, et al.
Clinical Chemistry and Laboratory Medicine|September 26, 2009
Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?Carsten Stephan, Thomas Köpke, Axel Semjonow, et al.
International Journal of Oncology|December 9, 2004
Cytogenetic changes and loss of heterozygosity in atypical adenomatous hyperplasia, in carcinoma of the prostate and in non-neoplastic prostate tissue using comparative genomic hybridization and multiplex-PCROlaf Bettendorf, Hartmut Schmidt, Elke Eltze, et al.
Journal of Medical Systems|September 12, 2013
Linkage of data from diverse data sources (LDS): a data combination model provides clinical data of corresponding specimens in biobanking information systemOkyaz Eminaga, Enver Özgür, Axel Semjonow, et al.
Pageof 11

Showing results (21-30 of 102) with videos related to

Sort By:
Pageof 11
Urology|June 18, 2003
Bicycle riding has no important impact on total and free prostate-specific antigen serum levels in older menHans-Joachim Luboldt, Klaus D Peck, Frank Oberpenning, et al.
Urologic Oncology|December 17, 2013
Tumor percentage but not number of tumor foci predicts disease-free survival after radical prostatectomy especially in high-risk patientsReemt Hinkelammert, Okyaz Eminaga, Olaf Bettendorf, et al.
International Journal of Molecular Sciences|September 13, 2016
Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate CancerKatrin Schlack, Laura-Maria Krabbe, Manfred Fobker, et al.
Urologic Oncology|February 26, 2013
The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/mlOkyaz Eminaga, Reemt Hinkelammert, Ulf Titze, et al.
Acta Oncologica (Stockholm, Sweden)|May 25, 2011
Tumor markers in prostate cancer I: blood-based markersShahrokh F Shariat, Axel Semjonow, Hans Lilja, et al.
The Prostate|March 28, 2013
High-grade prostatic intraepithelial neoplasia (HGPIN) and topographical distribution in 1,374 prostatectomy specimens: existence of HGPIN near prostate cancerOkyaz Eminaga, Reemt Hinkelammert, Mahmoud Abbas, et al.
Reviews in Urology|October 16, 2007
Twenty Years of PSA: From Prostate Antigen to Tumor MarkerGabriela De Angelis, Harry G Rittenhouse, Stephen D Mikolajczyk, et al.
Clinical Chemistry and Laboratory Medicine|September 26, 2009
Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?Carsten Stephan, Thomas Köpke, Axel Semjonow, et al.
International Journal of Oncology|December 9, 2004
Cytogenetic changes and loss of heterozygosity in atypical adenomatous hyperplasia, in carcinoma of the prostate and in non-neoplastic prostate tissue using comparative genomic hybridization and multiplex-PCROlaf Bettendorf, Hartmut Schmidt, Elke Eltze, et al.
Journal of Medical Systems|September 12, 2013
Linkage of data from diverse data sources (LDS): a data combination model provides clinical data of corresponding specimens in biobanking information systemOkyaz Eminaga, Enver Özgür, Axel Semjonow, et al.
Pageof 11